NGM · Financial Statements
Liminatus Pharma, Inc. (LIMN) Financial Statements
$3.76
NGM: LIMN
Market Cap $5.05M
Overview Financials Dividend Liminatus Pharma, Inc. most recently reported annual revenue of $0, net profit of $-10.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Annual Financials (USD)
Metric 2021 2022 2023 2024 2025 Revenue $0 $0 $0 $0 $0 Operating Profit $-3.0M $-3.0M $-3.0M $-3.0M $-3.0M Net Profit $4.0M $-3.0M $-1.0M $-3.0M $-10.0M EPS $6.50 $-4.11 $-7.50 $-20.00 $-21.50 Op Margin — — — — —
Balance Sheet (USD)
Metric 2021 2022 2023 2024 2025 Total Assets $276.0M $15.0M $5.0M $3.0M $1.0M Total Liabilities $22.0M $14.0M $15.0M $19.0M $10.0M Cash $0 $5.0M $0 $1.0M $0 Borrowings $0 $17.0M $16.0M $5.0M $1.0M
Cash Flow (USD)
Metric 2021 2022 2023 2024 2025 Operating Cash Flow $-1.0M $-1.0M $-3.0M $-3.0M $-10.0M Investing Cash Flow $-276.0M $0 $-1.0M $2.0M $-1.0M Financing Cash Flow $-6.0M $-1.0M $0 $-2.0M $-3.0M Net Cash Flow $0 $5.0M $-5.0M $1.0M $0 Free Cash Flow $-1.0M $-1.0M $-3.0M $-3.0M $-10.0M
Valuation & Return Ratios
Metric Value PEG Ratio 0.00 EV / EBITDA -0.24 FCF Yield -86.77% Quick Ratio 1.12 Interest Coverage -53.78 Return 1Y -97.95% Return 3Y — Return 5Y —
Screens featuring this stock